Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 19, 2025The Journal of Haemophilia PracticeOpen Access

Use of extended half-life factor IX products in the surgical setting: case series from a UK haemophilia centre

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMolly NdebeleECEmma CharnickNANawal Asir

Discussion

Loading...

Member takes

Overview

Case series reveals outpatient surgeries possible with extended half-life factor IX, highlighting reduced bleeding risks.

Key Points

  • EHL FIX products allowed successful surgeries without continuous infusion, enhancing patient care.
  • In 22 surgeries performed, only a single infusion was needed for many minor and major procedures.
  • The reduced dosing frequency of EHL FIX led to shorter hospital stays and decreased postoperative complications.
  • Use of EHL FIX reduced overall costs and resource demands in surgical management for patients with haemophilia.

Cite This Study

Ndebele et al. (2025) studied this question.

synapsesocial.com/papers/68d464e031b076d99fa63ca6https://doi.org/10.2478/jhp-2025-0012
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcome of Surgical Interventions in Patients with Haemophilia A and B Treated with Extended Half-Life (EHL) Factor Concentrates in a Single Centre.2025
  2. 2Real-World Use of Extended Half-Life Factor IX in Children with Haemophilia B2025
  3. 3Extended Half-Life Factor Concentrates in Haemophilia Treatment2026 · 1 citations
  4. 4Advantages of FVIII-Extended Half-Life (Turoctocog Alfa Pegol) in the Management of Cardiac Surgery in a Patient with Mild Hemophilia A: A Case Report and Literature Review2025
  5. 5Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX–Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective–Prospective Study2024 · 7 citations